Back to News
Market Impact: 0.2
BridgeBio Reports Cardiac Data From 12-month Interim Analysis Of FORTIFY Trial With BBP-418
Source: Nasdaq
Healthcare & Biotech
BridgeBio Pharma presented exploratory cardiac data from the 12-month interim analysis of its Phase 3 FORTIFY trial of oral BBP-418 in people with limb-girdle muscular dystrophy type 2I/R9. The provided article text ends before describing the cardiac findings, so their direction and clinical significance cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
BBIO0.65
More News
- TD Cowen reiterates Buy on BridgeBio Pharma stock, cites cardiac data
- Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI in Asset Management: 2026 Statistics That Hold Up
- What is Broker Research and RMS Systems (And How to Actually Use Them)